{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T03:38:57Z","timestamp":1769571537972,"version":"3.49.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11255-022-03107-6","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T08:03:22Z","timestamp":1642579402000},"page":"479-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["An indirect comparison meta-analysis of noninvasive intravesical instillation and intravesical injection of botulinum toxin-A in bladder disorders"],"prefix":"10.1007","volume":"54","author":[{"given":"Gao","family":"Yunfeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Junbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Dingyuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2024-155X","authenticated-orcid":false,"given":"Huang","family":"Chaoyou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"issue":"3","key":"3107_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/13697137.2018.1552254","volume":"22","author":"D Robinson","year":"2019","unstructured":"Robinson D, Cardozo L (2019) Managing overactive bladder. Climacteric 22(3):250\u2013256. https:\/\/doi.org\/10.1080\/13697137.2018.1552254","journal-title":"Climacteric"},{"issue":"2","key":"3107_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1055\/s-0038-1676089","volume":"36","author":"I Marcu","year":"2018","unstructured":"Marcu I, Campian EC, Tu FF (2018) Interstitial cystitis\/bladder pain syndrome. Semin Reprod Med 36(2):123\u2013135. https:\/\/doi.org\/10.1055\/s-0038-1676089","journal-title":"Semin Reprod Med"},{"issue":"5","key":"3107_CR3","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/nau.24382","volume":"39","author":"YC Chuang","year":"2020","unstructured":"Chuang YC, Meng E, Chancellor M, Kuo HC (2020) Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis\/bladder pain syndrome-A prospective, multicenter, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 39(5):1505\u20131514. https:\/\/doi.org\/10.1002\/nau.24382","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"3107_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/nau.23244","volume":"37","author":"DK Newman","year":"2018","unstructured":"Newman DK, Borello-France D, Sung VW (2018) Structured behavioral treatment research protocol for women with mixed urinary incontinence and overactive bladder symptoms. Neurourol Urodyn 37(1):14\u201326. https:\/\/doi.org\/10.1002\/nau.23244","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"3107_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner DJ, Gomelsky A, Souter L, Vasavada SP (2019) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019. J Urol 202(3):558\u2013563. https:\/\/doi.org\/10.1097\/JU.0000000000000309","journal-title":"J Urol"},{"issue":"5","key":"3107_CR6","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","volume":"193","author":"PM Hanno","year":"2015","unstructured":"Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological Association (2015) Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment. J Urol 193(5):1545\u20131553. https:\/\/doi.org\/10.1016\/j.juro.2015.01.086","journal-title":"J Urol"},{"issue":"6","key":"3107_CR7","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","volume":"75","author":"B Peyronnet","year":"2019","unstructured":"Peyronnet B, Mironska E, Chapple C et al (2019) A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol 75(6):988\u20131000. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.038","journal-title":"Eur Urol"},{"issue":"6","key":"3107_CR8","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00404-017-4364-2","volume":"295","author":"SS Patnaik","year":"2017","unstructured":"Patnaik SS, Lagan\u00e0 AS, Vitale SG et al (2017) Etiology, pathophysiology and biomarkers of interstitial cystitis\/painful bladder syndrome. Arch Gynecol Obstet 295(6):1341\u20131359. https:\/\/doi.org\/10.1007\/s00404-017-4364-2","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"3107_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/nau.2094","volume":"21","author":"J Ahlberg","year":"2002","unstructured":"Ahlberg J, Edlund C, Wikkels\u00f6 C, Rosengren L, Fall M (2002) Neurological signs are common in patients with urodynamically verified \u201cidiopathic\u201d bladder overactivity. Neurourol Urodyn 21(1):65\u201370. https:\/\/doi.org\/10.1002\/nau.2094","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"3107_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/nau.23834","volume":"38","author":"RH Ali","year":"2019","unstructured":"Ali RH, Gadallah NA, El Zohiery AK, Elwy M, Serag I (2019) Neurophysiologic study in idiopathic overactive bladder. Neurourol Urodyn 38(1):223\u2013230. https:\/\/doi.org\/10.1002\/nau.23834","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"3107_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5301\/RU.2012.8972","volume":"79","author":"E Sacco","year":"2012","unstructured":"Sacco E (2012) Fisiopatologia della vescica iperattiva [Physiopathology of overactive bladder syndrome]. Urologia 79(1):24\u201335. https:\/\/doi.org\/10.5301\/RU.2012.8972","journal-title":"Urologia"},{"issue":"5","key":"3107_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1308\/003588408X301217","volume":"90","author":"A Ballaro","year":"2008","unstructured":"Ballaro A (2008) The elusive electromyogram in the overactive bladder: a spark of understanding. Ann R Coll Surg Engl 90(5):362\u2013367","journal-title":"Ann R Coll Surg Engl"},{"issue":"6","key":"3107_CR13","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s10753-017-0643-0","volume":"40","author":"L Zhang","year":"2017","unstructured":"Zhang L, Ihsan AU, Cao Y et al (2017) An immunogenic peptide, T2 induces interstitial cystitis\/painful bladder syndrome: an autoimmune mouse model for interstitial cystitis\/painful bladder syndrome. Inflammation 40(6):2033\u20132041. https:\/\/doi.org\/10.1007\/s10753-017-0643-0","journal-title":"Inflammation"},{"issue":"9","key":"3107_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10719-014-9564-4","volume":"31","author":"I K\u0105tnik-Prastowska","year":"2014","unstructured":"K\u0105tnik-Prastowska I, Lis J, Matejuk A (2014) Glycosylation of uroplakins. Implications for bladder physiopathology. Glycoconj J 31(9):623\u2013636. https:\/\/doi.org\/10.1007\/s10719-014-9564-4","journal-title":"Glycoconj J"},{"key":"3107_CR15","doi-asserted-by":"publisher","unstructured":"Aizawa N (2019) Nihon Yakurigaku Zasshi. 154(5):255\u2013258. https:\/\/doi.org\/10.1254\/fpj.154.255","DOI":"10.1254\/fpj.154.255"},{"issue":"4","key":"3107_CR16","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/S0022-5347(05)67203-5","volume":"164","author":"CL Parsons","year":"2000","unstructured":"Parsons CL, Bautista SL, Stein PC, Zupkas P (2000) Cyto-injury factors in urine: a possible mechanism for the development of interstitial cystitis. J Urol 164(4):1381\u20131384","journal-title":"J Urol"},{"issue":"1","key":"3107_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/bju.13457","volume":"118","author":"SK Keay","year":"2016","unstructured":"Keay SK, Zhang CO (2016) Abnormal Akt signalling in bladder epithelial cell explants from patients with interstitial cystitis\/bladder pain syndrome can be induced by antiproliferative factor treatment of normal bladder cells. BJU Int 118(1):161\u2013172. https:\/\/doi.org\/10.1111\/bju.13457","journal-title":"BJU Int"},{"key":"3107_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3389\/fnins.2018.00931","volume":"12","author":"L Grundy","year":"2018","unstructured":"Grundy L, Caldwell A, Brierley SM (2018) Mechanisms underlying overactive bladder and interstitial cystitis\/painful bladder syndrome. Front Neurosci 12:931. https:\/\/doi.org\/10.3389\/fnins.2018.00931 (Published 2018 Dec 12)","journal-title":"Front Neurosci"},{"issue":"11","key":"3107_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00120-019-01054-2","volume":"58","author":"T Bschleipfer","year":"2019","unstructured":"Bschleipfer T, Doggweiler R, Schultz-Lampel D et al (2019) Diagnostik und therapie der interstitiellen zystitis (IC\/BPS): S2k-Leitlinie der Deutschen Gesellschaft f\u00fcr Urologie [Diagnosis and treatment of interstitial cystitis (IC\/PBS): S2k guideline of the German Society of Urology]. Urologe A. 58(11):1313\u20131323. https:\/\/doi.org\/10.1007\/s00120-019-01054-2 (published correction appears in Urologe A. 2019 Dec; 58(12):1498)","journal-title":"Urologe A."},{"issue":"3","key":"3107_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5603\/GP.2021.0046","volume":"92","author":"ME Grzybowska","year":"2021","unstructured":"Grzybowska ME, Rechberger T, Wrobel A et al (2021) The Urogynecology Section of the Polish Society of Gynecologists and Obstetricians guidelines on the management of non-neurogenic overactive bladder syndrome in women. Ginekol Pol 92(3):236\u2013251. https:\/\/doi.org\/10.5603\/GP.2021.0046","journal-title":"Ginekol Pol"},{"key":"3107_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/jog.14708","author":"VW Nitti","year":"2021","unstructured":"Nitti VW, Patel A, Karram M (2021) Diagnosis and management of overactive bladder: a review. J Obstet Gynaecol Res. https:\/\/doi.org\/10.1111\/jog.14708 (published online ahead of print, 2021 Feb 16)","journal-title":"J Obstet Gynaecol Res"},{"key":"3107_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/164_2019_308","volume":"263","author":"MB Chancellor","year":"2021","unstructured":"Chancellor MB, Smith CP (2021) Use of botulinum toxin in the genitourinary system. Handb Exp Pharmacol 263:171\u2013184. https:\/\/doi.org\/10.1007\/164_2019_308","journal-title":"Handb Exp Pharmacol"},{"issue":"Suppl 1","key":"3107_CR23","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.4111\/icu.2020.61.S1.S33","volume":"61","author":"JL Chen","year":"2020","unstructured":"Chen JL, Kuo HC (2020) Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol 61(Suppl 1):S33\u2013S42. https:\/\/doi.org\/10.4111\/icu.2020.61.S1.S33","journal-title":"Investig Clin Urol"},{"issue":"7","key":"3107_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/toxins8070201","volume":"8","author":"B Chiu","year":"2016","unstructured":"Chiu B, Tai HC, Chung SD, Birder LA (2016) Botulinum toxin A for bladder pain syndrome\/interstitial cystitis. Toxins (Basel). 8(7):201. https:\/\/doi.org\/10.3390\/toxins8070201 (Published 2016 Jul 1)","journal-title":"Toxins (Basel)."},{"issue":"2","key":"3107_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/toxins12020129","volume":"12","author":"YH Lin","year":"2020","unstructured":"Lin YH, Chiang BJ, Liao CH (2020) Mechanism of action of botulinum toxin A in treatment of functional urological disorders. Toxins (Basel). 12(2):129. https:\/\/doi.org\/10.3390\/toxins12020129 (Published 2020 Feb 18)","journal-title":"Toxins (Basel)."},{"issue":"8","key":"3107_CR26","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.3390\/toxins7083127","volume":"7","author":"HM Oh","year":"2015","unstructured":"Oh HM, Chung ME (2015) Botulinum toxin for neuropathic pain: a review of the literature. Toxins (Basel). 7(8):3127\u20133154. https:\/\/doi.org\/10.3390\/toxins7083127 (Published 2015 Aug 14)","journal-title":"Toxins (Basel)."},{"issue":"11","key":"3107_CR27","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.3390\/toxins7114519","volume":"7","author":"S Pellett","year":"2015","unstructured":"Pellett S, Yaksh TL, Ramachandran R (2015) Current status and future directions of botulinum neurotoxins for targeting pain processing. Toxins (Basel). 7(11):4519\u20134563. https:\/\/doi.org\/10.3390\/toxins7114519 (Published 2015 Nov 4)","journal-title":"Toxins (Basel)."},{"issue":"4","key":"3107_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/AJP.0000000000000538","volume":"34","author":"M Courseau","year":"2018","unstructured":"Courseau M, Salle PV, Ranoux D, de Pouilly LA (2018) Efficacy of intra-articular botulinum toxin in osteoarticular joint pain: a meta-analysis of randomized controlled trials. Clin J Pain 34(4):383\u2013389. https:\/\/doi.org\/10.1097\/AJP.0000000000000538","journal-title":"Clin J Pain"},{"issue":"9","key":"3107_CR29","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.3390\/toxins7093818","volume":"7","author":"S Luvisetto","year":"2015","unstructured":"Luvisetto S, Gazerani P, Cianchetti C, Pavone F (2015) Botulinum toxin type a as a therapeutic agent against headache and related disorders. Toxins (Basel). 7(9):3818\u20133844. https:\/\/doi.org\/10.3390\/toxins7093818 (Published 2015 Sep 23)","journal-title":"Toxins (Basel)."},{"issue":"12","key":"3107_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/toxins8120374","volume":"8","author":"D Machado","year":"2016","unstructured":"Machado D, Kumar A, Jabbari B (2016) Abobotulinum toxin A in the treatment of chronic low back pain. Toxins (Basel). 8(12):374. https:\/\/doi.org\/10.3390\/toxins8120374 (Published 2016 Dec 15)","journal-title":"Toxins (Basel)."},{"key":"3107_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.toxicon.2018.01.017","volume":"147","author":"Y Safarpour","year":"2018","unstructured":"Safarpour Y, Jabbari B (2018) Botulinum toxin treatment of pain syndromes -an evidence based review. Toxicon 147:120\u2013128. https:\/\/doi.org\/10.1016\/j.toxicon.2018.01.017","journal-title":"Toxicon"},{"issue":"1779","key":"3107_CR32","first-page":"1788","volume":"47","author":"Y Sun","year":"2015","unstructured":"Sun Y, Luo D, Tang C, Yang L, Shen H (2015) The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and metaanalysis. Int Urol Nephrol 47(1779):1788","journal-title":"Int Urol Nephrol"},{"issue":"704","key":"3107_CR33","first-page":"709","volume":"49","author":"A Giannantoni","year":"2006","unstructured":"Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006) Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 49(704):709","journal-title":"Eur Urol"},{"issue":"5","key":"3107_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","volume":"104","author":"HC Kuo","year":"2009","unstructured":"Kuo HC, Chancellor MB (2009) Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome. BJU Int 104(5):657\u2013661. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08495.x","journal-title":"BJU Int"},{"issue":"Suppl 1","key":"3107_CR35","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.4111\/icu.2020.61.S1.S33","volume":"61","author":"JL Chen","year":"2020","unstructured":"Noninvasive intravesical instillation of OBTX-A. 35, Chen JL, Kuo HC (2020) Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol. 61(Suppl 1):S33\u2013S42. https:\/\/doi.org\/10.4111\/icu.2020.61.S1.S33","journal-title":"Investig Clin Urol."},{"issue":"2","key":"3107_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/toxins12020098","volume":"12","author":"TC Yeh","year":"2020","unstructured":"Yeh TC, Chen PC, Su YR, Kuo HC (2020) Effect of botulinum toxin A on bladder pain-molecular evidence and animal studies. Toxins (Basel). 12(2):98. https:\/\/doi.org\/10.3390\/toxins12020098 (Published 2020 Feb 3)","journal-title":"Toxins (Basel)."},{"issue":"6","key":"3107_CR37","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.juro.2014.07.008","volume":"192","author":"YC Chuang","year":"2014","unstructured":"Chuang YC, Kaufmann JH, Chancellor DD, Chancellor MB, Kuo HC (2014) Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urol 192(6):1743\u20131749. https:\/\/doi.org\/10.1016\/j.juro.2014.07.008","journal-title":"J Urol"},{"issue":"6","key":"3107_CR38","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","volume":"65","author":"HC Kuo","year":"2014","unstructured":"Kuo HC, Liu HT, Chuang YC, Birder LA, Chancellor MB (2014) Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol 65(6):1117\u20131124. https:\/\/doi.org\/10.1016\/j.eururo.2014.01.036","journal-title":"Eur Urol"},{"issue":"3","key":"3107_CR39","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/21681805.2015.1121406","volume":"50","author":"J Krhut","year":"2016","unstructured":"Krhut J, Navratilova M, Sykora R et al (2016) Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: a double-blind randomized pilot study. Scand J Urol 50(3):200\u2013205. https:\/\/doi.org\/10.3109\/21681805.2015.1121406","journal-title":"Scand J Urol"},{"issue":"2","key":"3107_CR40","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.juro.2017.02.021","volume":"198","author":"YC Chuang","year":"2017","unstructured":"Chuang YC, Kuo HC (2017) A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxinA for interstitial cystitis\/bladder pain syndrome. J Urol 198(2):376\u2013382. https:\/\/doi.org\/10.1016\/j.juro.2017.02.021","journal-title":"J Urol"},{"issue":"3","key":"3107_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/s0090-4295(02)02281-1","volume":"61","author":"MO Fraser","year":"2003","unstructured":"Fraser MO, Chuang YC, Tyagi P et al (2003) Intravesical liposome administration\u2014a novel treatment for hyperactive bladder in the rat. Urology 61(3):656\u2013663. https:\/\/doi.org\/10.1016\/s0090-4295(02)02281-1","journal-title":"Urology"},{"issue":"6","key":"3107_CR42","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH et al (2012) Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6):940\u2013947. https:\/\/doi.org\/10.1016\/j.jval.2012.05.004","journal-title":"Value Health"},{"key":"3107_CR43","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898 (Published 2019 Aug 28)","journal-title":"BMJ"},{"key":"3107_CR44","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a metaanalysis. Stat Med 21:1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186 (PMID: 12111919)","journal-title":"Stat Med"},{"issue":"9","key":"3107_CR45","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/iju.12833","volume":"22","author":"Y Akiyama","year":"2015","unstructured":"Akiyama Y, Nomiya A, Niimi A et al (2015) Botulinum toxin type A injection for refractory interstitial cystitis: a randomized comparative study and predictors of treatment response. Int J Urol 22(9):835\u2013841. https:\/\/doi.org\/10.1111\/iju.12833","journal-title":"Int J Urol"},{"key":"3107_CR46","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/j.juro.2012.02.912","volume":"187","author":"G Kasyan","year":"2012","unstructured":"Kasyan G, Pushkar D (2012) Randomized controlled trial for efficacy of botulinum toxin type A in treatment of patients suffering bladder pain syndrome\/interstitial cystitis with Hunners Lesions: preliminary results. J Urol 187:e335\u2013e336","journal-title":"J Urol"},{"issue":"5","key":"3107_CR47","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/nau.22760","volume":"35","author":"HC Kuo","year":"2016","unstructured":"Kuo HC, Jiang YH, Tsai YC, Kuo YC (2016) Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment\u2014a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn 35(5):609\u2013614. https:\/\/doi.org\/10.1002\/nau.22760","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"3107_CR48","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00192-013-2267-8","volume":"25","author":"J Manning","year":"2014","unstructured":"Manning J, Dwyer P, Rosamilia A, Colyvas K, Murray C, Fitzgerald E (2014) A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis\/bladder pain syndrome. Int Urogynecol J 25(5):593\u2013599. https:\/\/doi.org\/10.1007\/s00192-013-2267-8","journal-title":"Int Urogynecol J"},{"issue":"2","key":"3107_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple C, Sievert KD, MacDiarmid S et al (2013) OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 64(2):249\u2013256. https:\/\/doi.org\/10.1016\/j.eururo.2013.04.001","journal-title":"Eur Urol"},{"issue":"3","key":"3107_CR50","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","volume":"61","author":"P Denys","year":"2012","unstructured":"Denys P, Le Normand L, Ghout I et al (2012) Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol 61(3):520\u2013529. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.028","journal-title":"Eur Urol"},{"issue":"6","key":"3107_CR51","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","volume":"184","author":"R Dmochowski","year":"2010","unstructured":"Dmochowski R, Chapple C, Nitti VW et al (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184(6):2416\u20132422. https:\/\/doi.org\/10.1016\/j.juro.2010.08.021","journal-title":"J Urol"},{"issue":"6","key":"3107_CR52","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1742-1241.2011.02663.x","volume":"65","author":"C Dowson","year":"2011","unstructured":"Dowson C, Sahai A, Watkins J, Dasgupta P, Khan MS (2011) The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial. Int J Clin Pract 65(6):698\u2013704. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02663.x","journal-title":"Int J Clin Pract"},{"issue":"6","key":"3107_CR53","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","volume":"181","author":"MK Flynn","year":"2009","unstructured":"Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD (2009) Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 181(6):2608\u20132615. https:\/\/doi.org\/10.1016\/j.juro.2009.01.117","journal-title":"J Urol"},{"issue":"2S","key":"3107_CR54","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.juro.2016.10.109","volume":"197","author":"VW Nitti","year":"2017","unstructured":"Nitti VW, Dmochowski R, Herschorn S et al (2017) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 197(2S):S216\u2013S223. https:\/\/doi.org\/10.1016\/j.juro.2016.10.109","journal-title":"J Urol"},{"issue":"4","key":"3107_CR55","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/nau.21021","volume":"30","author":"E Rovner","year":"2011","unstructured":"Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P (2011) Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 30(4):556\u2013562. https:\/\/doi.org\/10.1002\/nau.21021","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"3107_CR56","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P et al (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60(4):742\u2013750. https:\/\/doi.org\/10.1016\/j.eururo.2011.07.002","journal-title":"Eur Urol"},{"issue":"6","key":"3107_CR57","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","volume":"185","author":"S Herschorn","year":"2011","unstructured":"Herschorn S, Gajewski J, Ethans K et al (2011) Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol 185(6):2229\u20132235. https:\/\/doi.org\/10.1016\/j.juro.2011.02.004","journal-title":"J Urol"},{"issue":"3","key":"3107_CR58","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.urology.2009.05.097","volume":"75","author":"A Sahai","year":"2010","unstructured":"Sahai A, Dowson C, Khan MS, Dasgupta P, GKT Botulinum Study Group (2010) Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 75(3):552\u2013558. https:\/\/doi.org\/10.1016\/j.urology.2009.05.097","journal-title":"Urology"},{"issue":"3","key":"3107_CR59","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","volume":"62","author":"DG Tincello","year":"2012","unstructured":"Tincello DG, Kenyon S, Abrams KR et al (2012) Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 62(3):507\u2013514. https:\/\/doi.org\/10.1016\/j.eururo.2011.12.056","journal-title":"Eur Urol"},{"issue":"1","key":"3107_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/luts.12214","volume":"10","author":"E Meng","year":"2018","unstructured":"Meng E, Hsu YC, Chuang YC (2018) Advances in intravesical therapy for bladder pain syndrome (BPS)\/interstitial cystitis (IC). Low Urin Tract Symptoms 10(1):3\u201311. https:\/\/doi.org\/10.1111\/luts.12214","journal-title":"Low Urin Tract Symptoms"},{"issue":"3","key":"3107_CR61","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1442-2042.2011.02946.x","volume":"19","author":"T Yokoyama","year":"2012","unstructured":"Yokoyama T, Chancellor MB, Oguma K et al (2012) Botulinum toxin type A for the treatment of lower urinary tract disorders. Int J Urol 19(3):202\u2013215. https:\/\/doi.org\/10.1111\/j.1442-2042.2011.02946.x","journal-title":"Int J Urol"},{"issue":"3","key":"3107_CR62","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.urology.2007.04.038","volume":"70","author":"HT Liu","year":"2007","unstructured":"Liu HT, Kuo HC (2007) Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 70(3):463\u2013468. https:\/\/doi.org\/10.1016\/j.urology.2007.04.038","journal-title":"Urology"},{"issue":"1","key":"3107_CR63","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/nau.22508","volume":"34","author":"AT Hanna-Mitchell","year":"2015","unstructured":"Hanna-Mitchell AT, Wolf-Johnston AS, Barrick SR et al (2015) Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Neurourol Urodyn 34(1):79\u201384. https:\/\/doi.org\/10.1002\/nau.22508","journal-title":"Neurourol Urodyn"},{"issue":"6 Suppl","key":"3107_CR64","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1097\/00002508-200211001-00005","volume":"18","author":"MF Lew","year":"2002","unstructured":"Lew MF (2002) Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 18(6 Suppl):S142\u2013S146. https:\/\/doi.org\/10.1097\/00002508-200211001-00005","journal-title":"Clin J Pain"},{"issue":"Suppl 1","key":"3107_CR65","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10072-017-2884-y","volume":"38","author":"C Lovati","year":"2017","unstructured":"Lovati C, Giani L (2017) Action mechanisms of Onabotulinum toxin-A: hints for selection of eligible patients. Neurol Sci 38(Suppl 1):131\u2013140. https:\/\/doi.org\/10.1007\/s10072-017-2884-y","journal-title":"Neurol Sci"},{"issue":"11","key":"3107_CR66","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/toxins11110641","volume":"11","author":"JF Jhang","year":"2019","unstructured":"Jhang JF (2019) Using botulinum toxin A for treatment of interstitial cystitis\/bladder pain syndrome-possible pathomechanisms and practical issues. Toxins (Basel). 11(11):641. https:\/\/doi.org\/10.3390\/toxins11110641 (Published 2019 Nov 4)","journal-title":"Toxins (Basel)."},{"issue":"3","key":"3107_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11916-016-0545-0","volume":"20","author":"S Patil","year":"2016","unstructured":"Patil S, Willett O, Thompkins T et al (2016) Botulinum toxin: pharmacology and therapeutic roles in pain states. Curr Pain Headache Rep 20(3):15. https:\/\/doi.org\/10.1007\/s11916-016-0545-0","journal-title":"Curr Pain Headache Rep"},{"issue":"14","key":"3107_CR68","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1523\/JNEUROSCI.0375-08.2008","volume":"28","author":"F Antonucci","year":"2008","unstructured":"Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M (2008) Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28(14):3689\u20133696. https:\/\/doi.org\/10.1523\/JNEUROSCI.0375-08.2008","journal-title":"J Neurosci"},{"issue":"7","key":"3107_CR69","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.celrep.2016.06.104","volume":"16","author":"E Bomba-Warczak","year":"2016","unstructured":"Bomba-Warczak E, Vevea JD, Brittain JM et al (2016) Interneuronal transfer and distal action of tetanus toxin and botulinum neurotoxins A and D in central neurons. Cell Rep 16(7):1974\u20131987. https:\/\/doi.org\/10.1016\/j.celrep.2016.06.104","journal-title":"Cell Rep"},{"key":"3107_CR70","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.toxicon.2017.10.027","volume":"147","author":"M Caleo","year":"2018","unstructured":"Caleo M, Restani L (2018) Direct central nervous system effects of botulinum neurotoxin. Toxicon 147:68\u201372. https:\/\/doi.org\/10.1016\/j.toxicon.2017.10.027","journal-title":"Toxicon"},{"issue":"10","key":"3107_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047977","volume":"7","author":"S Marinelli","year":"2012","unstructured":"Marinelli S, Vacca V, Ricordy R et al (2012) The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS ONE 7(10):e47977. https:\/\/doi.org\/10.1371\/journal.pone.0047977","journal-title":"PLoS ONE"},{"issue":"4","key":"3107_CR72","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00192-016-3079","volume":"28","author":"W Zhang","year":"2017","unstructured":"Zhang W, Deng X, Liu C, Wang X (2017) Intravesical treatment for interstitial cystitis\/painful bladder syndrome: a network meta-analysis. Int Urogynecol J 28(4):515\u2013525. https:\/\/doi.org\/10.1007\/s00192-016-3079","journal-title":"Int Urogynecol J"},{"key":"3107_CR73","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.12659\/msm.897350","volume":"22","author":"J Wang","year":"2016","unstructured":"Wang J, Wang Q, Wu Q, Chen Y, Wu P (2016) Intravesical botulinum toxin A injections for bladder pain syndrome\/interstitial cystitis: a systematic review and meta-analysis of controlled studies. Med Sci Monit 22:3257\u20133267. https:\/\/doi.org\/10.12659\/msm.897350","journal-title":"Med Sci Monit"},{"issue":"5","key":"3107_CR74","doi-asserted-by":"publisher","first-page":"20f13681","DOI":"10.4088\/JCP.20f13681","volume":"81","author":"C Andrade","year":"2020","unstructured":"Andrade C (2020) Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry 81(5):20f13681. https:\/\/doi.org\/10.4088\/JCP.20f13681 (Published 2020 Sep 22)","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"3107_CR75","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s11255-016-1295-y","volume":"48","author":"SR Shim","year":"2016","unstructured":"Shim SR, Cho YJ, Shin IS, Kim JH (2016) Efficacy and safety of botulinum toxin injection for interstitial cystitis\/bladder pain syndrome: a systematic review and meta-analysis. Int Urol Nephrol 48(8):1215\u20131227. https:\/\/doi.org\/10.1007\/s11255-016-1295-y","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"3107_CR76","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/toxins11090510","volume":"11","author":"A Giannantoni","year":"2019","unstructured":"Giannantoni A, Gubbiotti M, Bini V (2019) Botulinum neurotoxin A intravesical injections in interstitial cystitis\/bladder painful syndrome: a systematic review with meta-analysis. Toxins (Basel). 11(9):510. https:\/\/doi.org\/10.3390\/toxins11090510 (Published 2019 Aug 30)","journal-title":"Toxins (Basel)."},{"issue":"4","key":"3107_CR77","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1055\/s-0038-1642631","volume":"40","author":"RM Arruda","year":"2018","unstructured":"Arruda RM, Takano CC, Gir\u00e3o MJBC, Haddad JM, Aleixo GF, Castro RA (2018) Treatment of non-neurogenic overactive bladder with OnabotulinumtoxinA: systematic review and meta-analysis of prospective, randomized, placebo-controlled clinical trials. Tratamento da bexiga hiperativa n\u00e3o neurog\u00eanica com toxina botul\u00ednica A: revis\u00e3o sistem\u00e1tica e metan\u00e1lise de ensaios cl\u00ednicos prospectivos, randomizados e placebo-controlados. Rev Bras Ginecol Obstet 40(4):225\u2013231. https:\/\/doi.org\/10.1055\/s-0038-1642631","journal-title":"Rev Bras Ginecol Obstet"},{"key":"3107_CR78","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.urology.2016.10.026","volume":"100","author":"H L\u00f3pez Ramos","year":"2017","unstructured":"L\u00f3pez Ramos H, Torres Castellanos L, Ponce Esparza I, Jaramillo A, Rodr\u00edguez A, Moreno BC (2017) Management of overactive bladder with onabotulinumtoxinA: systematic review and meta-analysis. Urology 100:53\u201358. https:\/\/doi.org\/10.1016\/j.urology.2016.10.026","journal-title":"Urology"},{"key":"3107_CR79","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.urology.2018.11.037","volume":"125","author":"HY Lee","year":"2019","unstructured":"Lee HY, Doo SW, Yang WJ et al (2019) Efficacy and safety of noninvasive intravesical instillation of onabotulinum toxin-A for overactive bladder and interstitial cystitis\/bladder pain syndrome: systematic review and meta-analysis. Urology 125:50\u201357. https:\/\/doi.org\/10.1016\/j.urology.2018.11.037","journal-title":"Urology"},{"issue":"4","key":"3107_CR80","first-page":"e181","volume":"12","author":"J Kaufman","year":"2010","unstructured":"Kaufman J, Tyagi V, Anthony M, Chancellor MB, Tyagi P (2010) State of the art in intravesical therapy for lower urinary tract symptoms. Rev Urol 12(4):e181\u2013e189","journal-title":"Rev Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03107-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T13:28:31Z","timestamp":1644499711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03107-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3107"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03107-6","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}